Active Biotech Q1 2025: Important results with laquinimod - Redeye

Redeye comments on Active Biotech’s Q1 report 2025. In May, the company reported positive topline data in the biodistribution study of tasquinimod, potentially setting it up for a deal. The first patients were recruited to the American and European studies of tasquinimod in myelofibrosis. Importantly, NeoTX has continued its study of naptumomab, which we consequently add back to our base case.

Länk till analysen i sin helhet: https://www.redeye.se/research/1105671/active-biotech-q1-2025-important-results-with-laquinimod?utm_source=finwire&utm_medium=RSS